InsidersTradesSigma
Total declarations
Companies
▲ Purchases (17 ops.)
▼ Sales (6 ops.)
Insider track record
OtherDisclosed buys
17
Disclosed sells
6
T+90 hit rate
100%
T+90 mean return
+40.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by BIOTECH GROWTH N V. Insider active across 3 companies, notably ESSA Pharma Inc.. Cumulatively, 23 reports have been logged. Split: 17 buys · 6 sells. Total volume traded: €41m. History available since 18 August 2021. The latest transaction was disclosed on 19 March 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations23 total
1,000,000 shares@ US$2.069110.4% of flowCommon StockSEC:0001104659-25-026305:0
2,000,000 shares@ US$1.529412.3% of flowCommon SharesSEC:0000950170-24-121206:2
1,879,583 shares@ US$1.51311.5% of flowCommon SharesSEC:0000950170-24-121206:3
2,000,000 shares@ US$1.53212.4% of flowCommon SharesSEC:0000950170-24-121206:0
2,000,000 shares@ US$1.525912.3% of flowCommon SharesSEC:0000950170-24-121206:1
400,000 shares@ US$2.33524.8% of flowCommon StockSEC:0000950170-23-054142:0
Ideal exit: 13 Jul 2024 (T+270)
1,000,000 shares@ US$5.0025.2% of flowCommon StockSEC:0000950170-23-031386:0
Ideal exit: 26 Mar 2024 (T+270)
1,740,000 shares@ US$5.491447.8% of flowCommon StockSEC:0000899243-23-016705:0
Ideal exit: 23 Mar 2024 (T+270)
99,801 shares@ US$2.25361.2% of flowCommon StockSEC:0000899243-22-034751:0
Ideal exit: 28 Jul 2023 (T+270)
191,678 shares@ US$1.87412.0% of flowCommon StockSEC:0000899243-22-034543:0
Ideal exit: 24 Jul 2023 (T+270)
1,500,000 shares@ US$3.97926.0% of flowCommon SharesSEC:0000899243-22-034401:0
Ideal exit: 23 Jul 2023 (T+270)
87,850 shares@ US$1.51110.7% of flowCommon StockSEC:0000899243-22-034121:0
Ideal exit: 18 Jul 2023 (T+270)
77,689 shares@ US$1.32290.6% of flowCommon StockSEC:0000899243-22-033945:0
Ideal exit: 16 Jul 2023 (T+270)
300,000 shares@ US$3.15584.1% of flowCommon SharesSEC:0000899243-22-026410:0
Ideal exit: 14 Apr 2023 (T+270)
347,204 shares@ US$2.79214.2% of flowCommon SharesSEC:0000899243-22-026225:0
Ideal exit: 10 Apr 2023 (T+270)
150,000 shares@ US$2.66320.27% mcap28.9% of flowCommon StockSEC:0000899243-22-016006:0
Ideal exit: 22 Jan 2023 (T+270)
25,100 shares@ US$5.85363.5% of flowCommon SharesSEC:0000899243-22-015831:0
150,000 shares@ US$3.29290.33% mcap34.9% of flowCommon StockSEC:0000899243-22-015145:0
Ideal exit: 13 Jan 2023 (T+270)
150,000 shares@ US$3.4240.34% mcap36.2% of flowCommon StockSEC:0000899243-22-014768:0
Ideal exit: 7 Jan 2023 (T+270)
250,000 shares@ US$8.875248.2% of flowCommon SharesSEC:0000899243-21-033765:0
Ideal exit: 15 May 2022 (T+270)
250,000 shares@ US$8.87528.3% of flowCommon SharesSEC:0000899243-21-033765
Ideal exit: 15 May 2022 (T+270)
38,259 sharesCommon StockSEC:0000899243-16-012141:0
Ideal exit: 18 Oct 2016 (T+270)
50,000 sharesCommon StockSEC:0000899243-16-011711:0
Ideal exit: 9 Oct 2016 (T+270)
23 of 23 declarations
About BIOTECH GROWTH N V
BIOTECH GROWTH N V is a director at ESSA Pharma Inc. and is also associated with Black Diamond Therapeutics, Inc.
